Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Xiangjuan, Ma"'
Autor:
Panpan Zhang, Minting Ma, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Di Wu, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Qianyun Hao, Jian Fang
Publikováno v:
Heliyon, Vol 10, Iss 4, Pp e26026- (2024)
Purpose: The purpose of this study is to investigate the efficacy and safety of immune checkpoint inhibitors (ICIs) or plus with chemotherapy in older patients. Methods: We enrolled 110 older patients with non-small cell lung cancer (NSCLC ≥75 year
Externí odkaz:
https://doaj.org/article/3f6dc24e9ea14686aec8d5b8224420b6
Autor:
Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Sen Han, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Di Wu, Ziran Zhang, Jieran Long, Jian Fang
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-17 (2023)
Abstract Background Lung Adenocarcinoma (LUAD) is a major component of lung cancer. Endoplasmic reticulum stress (ERS) has emerged as a new target for some tumor treatments. Methods The expression and clinical data of LUAD samples were downloaded fro
Externí odkaz:
https://doaj.org/article/59ff762cbd314f2891c656e359565252
Autor:
Yang Wang, Xuanye Zhang, Dan Tian, Sen Han, Jie Zhang, Jun Nie, Ling Dai, Weiheng Hu, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Di Wu, Ziran Zhang, Jieran Long, Jian Fang
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2303-2311 (2023)
Abstract Background Currently there is no standard therapy recommended for second‐line treatment for thymic carcinoma. Our study compared multidrug chemotherapy, single‐agent chemotherapy, and PD‐1 inhibitors in patients diagnosed with advanced
Externí odkaz:
https://doaj.org/article/c14739a621ec4157b7d0b15363ae0eff
Autor:
Huajun Feng, Liyang Xu, Ruya Chen, Xiangjuan Ma, Hua Qiao, Nannan Zhao, Yangcheng Ding, Di Wu
Publikováno v:
Frontiers in Microbiology, Vol 13 (2022)
Remediation of environmental toxic pollutants has attracted extensive attention in recent years. Microbial bioremediation has been an important technology for removing toxic pollutants. However, microbial activity is also susceptible to toxicity stre
Externí odkaz:
https://doaj.org/article/78d2bda1123243c8994249ae3b182603
Autor:
Xiangjuan Ma, Ziran Zhang, Xiaoling Chen, Jie Zhang, Jun Nie, Ling Da, Weiheng Hu, Guangming Tian, Di Wu, Jindi Han, Sen Han, Jieran Long, Yang Wang, Jian Fang
Publikováno v:
Thoracic Cancer, Vol 12, Iss 12, Pp 1841-1850 (2021)
Abstract Background Small cell lung cancer (SCLC) is characterized by aggressive spread and poor prognosis, but has limited treatment options. Results of prognostic factors from randomized trials on treatment arrangement are conflicting and large‐s
Externí odkaz:
https://doaj.org/article/eba69f95fa38422da4d3181c6d7446ec
Autor:
Jie Zhang PhD, Di Wu PhD, Ziran Zhang PhD, Jieran Long PhD, Guangming Tian PhD, Yang Wang PhD, Xiangjuan Ma PhD, Xiaoling Chen PhD, Jindi Han PhD, Weiheng Hu PhD, Ling Dai PhD, Jun Nie PhD, Jian Fang PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Objective: Pembrolizumab and bevacizumab both have antitumor activity. According to NCCN updated guideline the benefit of pembrolizumab or bevacizumab as a first line in management of advanced nonsmall cell lung cancer (NSCLC) is documented in random
Externí odkaz:
https://doaj.org/article/31934071c47149bf87053edf3807d5a3
Autor:
Yang Wang, Qianyun Hao, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Jindi Han, Sen Han, Di Wu, Jieran Long, Ziran Zhang, Jian Fang
Publikováno v:
Anti-Cancer Drugs; Jun2024, Vol. 35 Issue 5, p412-417, 6p
Autor:
Di Wu, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Jindi Han, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Jian Fang
Publikováno v:
Thoracic Cancer, Vol 10, Iss 7, Pp 1590-1596 (2019)
Background This real‐world study assessed the efficacy and toxicity of anlotinib as salvage treatment in Chinese patients with advanced non‐small cell lung cancer (NSCLC). Methods The medical records of 81 patients with advanced NSCLC who had fai
Externí odkaz:
https://doaj.org/article/056f8498d2aa4d4c81185921e619bab5
Autor:
Jie Zhang, Chen Tian, Fang Lv, Jianfei Wang, Wenbo Han, Jun Nie, Ling Dai, Weiheng Hu, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Di Wu, Sen Han, Yang Wang, Jieran Long, Ziran Zhang, Jian Fang, Henghui Zhang
Publikováno v:
Cancer Communications, Vol 39, Iss 1, Pp 1-5 (2019)
Externí odkaz:
https://doaj.org/article/6fbb8e0ef6ed47ed852b8d912ac453e7
Autor:
Yang Wang, Jun Nie, Ling Dai, Weiheng Hu, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Ziran Zhang, Jian Fang
Publikováno v:
Thoracic Cancer, Vol 10, Iss 1, Pp 17-23 (2019)
Background Thymoma and thymic carcinoma are rare thymic epithelial tumors. We investigated the efficacy of first‐line gemcitabine and cisplatin (GP) chemotherapy versus gemcitabine and cisplatin chemotherapy combined with the anti‐angiogenic drug
Externí odkaz:
https://doaj.org/article/97aa73763f3e4c0db10a54176f882449